- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | What to Expect from P3 Health Partners' Earnings | 1 | Benzinga.com | ||
| 04.04. | P3 Health Partners Announces 1-for-50 Reverse Stock Split | - | Investing.com | ||
| 04.04. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | P3 Health Partners Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
| 28.03. | P3 Health stock neutral rating reiterated after earnings miss | 2 | Investing.com | ||
| 28.03. | P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M | 1 | Seeking Alpha | ||
| 13.02. | P3 Health Partners strebt Profitabilität bis 2025 mit Umsatz von bis zu 1,5 Milliarden US-Dollar an | 11 | Investing.com Deutsch | ||
| 13.02. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.24 | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 183 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
| 07.08.24 | P3 Health Partners Announces Second Quarter 2024 Results | 139 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,133 | -2,21 % | Sernova Biotherapeutics Inc: Sernova talks interim data from Cell Pouch trial | ||
| ATOSSA THERAPEUTICS | 0,905 | +16,32 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen | Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,802 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,015 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,244 | -21,29 % | Co-Diagnostics GAAP EPS of -$0.24 beats by $0.03, revenue of $0.05M misses by $0.14M | ||
| CYTOSORBENTS | 0,697 | -6,82 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| VERU | 0,450 | -0,49 % | JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level | Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| VOLITIONRX | 0,465 | -2,52 % | VolitionRX Q1 2025 Earnings Preview | ||
| EKSO BIONICS | 0,409 | +2,25 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Accepted into NVIDIA Connect Program | ||
| IMUNON | 0,540 | -1,82 % | Imunon, Inc.: IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 | Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications... ► Artikel lesen | |
| BEYOND AIR | 0,170 | +3,03 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger Inc - 8-K, Current Report | ||
| NOVACYT | 0,469 | +0,11 % | Novacyt announces AGM scheduled for June 19, 2025 | ||
| AROVELLA THERAPEUTICS | 0,042 | 0,00 % | Biocurious: With its 'molecular Lego' approach, Arovella is building hope for cancer patients one brick at a time |
P3 HEALTH PARTNERS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 7,950 Euro und damit -2,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu P3 HEALTH PARTNERS INC finden Sie auf Wallstreet Online.